XML 42 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions (Details Narrative)
1 Months Ended 3 Months Ended 9 Months Ended 11 Months Ended
May 11, 2017
$ / shares
shares
Mar. 01, 2017
shares
Feb. 10, 2017
shares
Feb. 02, 2017
shares
Jan. 10, 2017
shares
Sep. 09, 2016
USD ($)
$ / shares
shares
Mar. 15, 2016
$ / shares
shares
Feb. 02, 2016
USD ($)
$ / shares
shares
May 01, 2015
USD ($)
Installment
Jul. 21, 2017
USD ($)
$ / shares
shares
Jun. 28, 2017
USD ($)
$ / shares
shares
Mar. 01, 2017
shares
Feb. 28, 2017
shares
Feb. 23, 2017
USD ($)
Feb. 17, 2017
shares
Sep. 25, 2014
USD ($)
Installment
Sep. 30, 2017
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
$ / shares
May 11, 2018
$ / shares
Dec. 31, 2016
USD ($)
Common stock shares reserved for future issuance | shares                                 102,582   102,582      
Stock option grant vested | $ / shares                                     $ 3.38 $ 1.41 $ 37,500  
Accounts payable                                 $ 20,000   $ 20,000     $ 33,290
Research and development expense                                 $ 139,819 $ 45,381 $ 363,785 $ 231,013    
Exercise Price | $ / shares                                 $ 3.09   $ 3.09      
Charitable Grant Agreement [Member]                                            
Donation to the University                               $ 75,000            
Donation periodic payment                               $ 9,375            
Number of installments | Installment                               8            
Dr. Gerlach [Member]                                            
Compensation expense for services                                 $ 10,000 9,200 $ 28,540 33,210    
Accounts payable                                 10,000   10,000     18,540
Joseph Sierchio [Member]                                            
Annual retainer payable                                 6,000   $ 6,000      
Common stock shares reserved for future issuance | shares 75,000           50,000                              
Exercise price | $ / shares $ 4.20                                   $ 1.91      
Legal fees                                 15,115 30,080 $ 195,783 121,595    
Accounts payable                                 10,000   10,000     11,750
Kenneth Kirkland [Member]                                            
Annual retainer payable                                 6,000   6,000      
Common stock shares reserved for future issuance | shares 75,000           50,000                              
Exercise price | $ / shares $ 4.20           $ 1.91                              
Option agreement [Member] | Dr. Gerlach [Member]                                            
Number of installments | Installment                 4                          
Fees payable under agreement                 $ 24,000                          
Due to related party periodic payment                 6,000                          
Research and development expense                 $ 24,000                          
Series A [Member] | Dr. Gerlach [Member]                                            
Common stock shares reserved for future issuance | shares         240,000                                  
Debt conversion converted instrument shares issued | shares         204,571                                  
KCC [Member] | Loan agreement [Member]                                            
Convertible debt financing, Maximum amount           $ 900,000                                
Convertible debt financing, Loan received           700,000               $ 395,000                
Convertible debt financing, Remaining amount           $ 200,000                                
Interest rate           7.00%               7.00%                
Maturity date           Dec. 31, 2017               Feb. 23, 2018                
Debt instrument conversion feature           (i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23.               (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.                
Debt instrument floor price | $ / shares           $ 1.23                                
KCC [Member] | Series B and C warrants [Member]                                            
Debt conversion converted instrument shares issued | shares   4,273,831                                        
KCC [Member] | Series C Warrant [Member]                                            
Number of warrants exercised | shares                       3,092,637                    
KCC [Member] | Series B Warrant [Member]                                            
Number of warrants exercised | shares                       1,326,087                    
Debt conversion converted instrument shares issued | shares               2,173,913                            
Exercise Price | $ / shares               $ 0.46                            
Proceeds from issuance of common stock               $ 1,000,000                            
KCC [Member] | Series F Warrant [Member]                                            
Number of warrants exercised | shares                     114,493                      
Debt conversion converted instrument shares issued | shares                     114,493                      
Exercise Price | $ / shares                     $ 3.01                      
Proceeds from issuance of common stock                     $ 344,624                      
KCC [Member] | Series F Warrant [Member] | Loan agreement [Member]                                            
Common stock shares reserved for future issuance | shares                         114,493                  
Debt instrument conversion feature                         (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant.                  
Warrant expiration period                         5 years                  
KCC [Member] | Series E Warrant [Member] | Loan agreement [Member]                                            
Common stock shares reserved for future issuance | shares           584,416                                
Debt instrument conversion feature           (i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant.                                
Warrant expiration period           5 years                                
KCC [Member] | Private Placement Member                                            
Common stock shares reserved for future issuance | shares                   410,000                        
Unit price per share | $ / shares                   $ 2.44                        
Proceeds from units reserved for future issuance                   $ 1,000,400                        
Terms of agreement                   Each unit consisted of one share of common stock and one Series G Warrant to purchase one (1) share of common stock at an exercise price of $2.68 per share through July 21, 2022. The warrants may be exercised on a cashless basis                        
KCC [Member] | Private Placement Member | Series G [Member]                                            
Exercise price | $ / shares                   $ 2.68                        
Joseph Sierchio [Member] | Loan agreement [Member]                                            
Convertible debt financing, Loan received                           $ 25,000                
Interest rate                           7.00%                
Maturity date                           Feb. 23, 2018                
Debt instrument conversion feature                           (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.                
Joseph Sierchio [Member] | Stock option [Member]                                            
Common stock shares reserved for future issuance | shares     70,000                                      
Debt conversion converted instrument shares issued | shares     38,642                                      
Joseph Sierchio [Member] | Series F Warrant [Member] | Loan agreement [Member]                                            
Common stock shares reserved for future issuance | shares                         7,246                  
Debt instrument conversion feature                         (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant.                  
Warrant expiration period                         5 years                  
Thomas bold [Member] | Stock option [Member]                                            
Common stock shares reserved for future issuance | shares                             40,000              
Debt conversion converted instrument shares issued | shares                             34,296              
Satterlee Stephens LLP [Member]                                            
Accounts payable                                           $ 11,750
StemCell Systems [Member]                                            
Incurred expenses                                 $ 39,708 $ 24,000 $ 146,538 $ 134,567    
Kenneth Kirkland [Member] | Stock option [Member]                                            
Common stock shares reserved for future issuance | shares       40,000                                    
Debt conversion converted instrument shares issued | shares       29,642